Tyme Technologies, Inc. is a biotech firm that is focused on developing cancer metabolism-based treatments that have low toxicity and can be effective for various kinds of tumors. The firm's approach leverages the innate weaknesses of cancer cells to lower their defenses, making them more susceptible to oxidative stress and the body's immune system response. This is different from targeted therapies that aim to regulate specific mutations in cancer. Tyme's strategy has shown promise in preclinical studies, and the firm is hoping to advance its research and development efforts in the coming years.